www.dailypolitical.com ·
Zacks Research Weighs in on Health in Tech Fy2026 Earnings
Topic context
This topic has been covered 280754 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThis is a single-company earnings projection for Health In Tech, a small-cap health technology firm. No broad sector or commodity impact. The commercial mechanism is weak: the article only contains analyst estimates and past earnings results, with no explicit revenue/cost driver, supply chain, or regulatory change. The company's primary sector is healthcare technology, but the impact is limited to the company itself.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Health In Tech (HIT) projected FY2026 EPS of ($0.06) by Zacks Research.
- HIT reported Q1 2026 loss of ($0.03) per share, beating consensus by $0.01.
- HIT Q1 2026 revenues were $8.77 million.
- HIT stock price $1.01, market cap $60.56 million, 52-week range $0.56-$4.02.
- Analyst consensus rating 'Buy' with target price $3.25.
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
proactiveinvestors.com.au
The Morning Catch Up Asx Set to Open Lower Ahead of Pivotal Nvidia Earnings
tickerreport.com
Roivant Sciences Nasdaqroiv Shares Gap Up on Strong Earnings
nbclosangeles.com